If future studies confirm the rescued receptors work normally, the study offers a new roadmap for rare disease drug development.

Most Americans learn as schoolchildren that our country is the greatest democracy in the world. Democracy is part of our national myth and, as such, the pretext for many of our most consequential and ...

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. Learn more about GPCR stock here.

Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic diseases such as obesity and diabetes.

Researchers have discovered how unstructured segments of surface proteins regulate the biological function of a cell. Their ...

Great. Thanks for joining us, everyone. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. I'm very pleased to be hosting Structure Therapeutics. Joining us today from the company, ...

Novels need a gripping story to stay popular as the decades pass, but it seems that other less-obvious factors may also ...

Aquaglyceroporin Aqp10, a protein channel for water and glycerol, selectively permeates urea and boric acid due to its unique ...

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...